New York City, NY -- (SBWIRE) -- 10/04/2013 -- StockMarketIntel.com issues a special report on the following stocks: AngioDynamics (NASDAQ:ANGO), Colonial Properties Trust Inc (NYSE:CLP), Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) ,Vical (NASDAQ:VICL)
AngioDynamics (NASDAQ:ANGO) declared the registration of the first patient at University of Miami Hospital in a randomized multi-center research finding whether the BioFlo PICC will be linked with a lowered incidence of catheter-associated venous thrombosis, consisting of both symptomatic and asymptomatic, in contrast to another commercially available PICC, the Bard PowerPICC SOLO2.
Has ANGO Found The Bottom And Ready To Gain Momentum? Find Out Here
Colonial Properties Trust Inc (NYSE:CLP) settled -0.53% lower at $22.37 on high volume of 18.95 million shares during the last trading day. The stock has its 12-month high at $25.27 and 52-week low price was $19.79.
Colonial Properties Trust (the Trust) is a multifamily-focused self-administered equity real estate investment trust (REIT) that owns, operates and develops multifamily communities primarily located in the Sunbelt region of the United States.
Why Should Investors Buy CLP After the Recent Fall? Just Go Here and Find Out
Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) saw its price fall on below-normal volume, as 13.87 million shares changed hands when compared with its average daily volume of 10.37 million shares. The stock was down -2.09% to clsoe at $10.79.
Will HIMX Get Buyers Even After The Recent Rally? Find Out Here
Himax Technologies, Inc. operates as an IC design house with LCD manufacturing capability. The Company focuses on display IC products for display device and offers LCD technical consulting to customers to provide them with value-added technical support and integrated solutions.
Vical (NASDAQ:VICL) declared the publication of a fresh article in a special DNA vaccine issue of the journal Vaccines explaining the development process from early product concept to Phase 3 trial initiation for ASP0113 (TransVax), co's investigational therapeutic vaccine designed to control cytomegalovirus in transplant recipients.
Is VICL a Solid Investment at These Levels? Read This Report For Details
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)